Novartis (NVS, $94.86) acquires IFM Tre, enlarges medicine portfolio
In a recent announcement, Novartis confirmed its acquisition of IFM Tre, a subsidiary of IFM Therapeutics LLC that specializes in developing anti-inflammatory medicines, especially the NLRP3 inflammasome. This latest acquisition will now add to the company’s immunomodulatory medicine portfolio.
Valued at $1.575 billion, according to the terms of the deal, Novartis would pay $310 million upfront and then become eligible to pay for as much as $1.265 billion in milestone payments.
The acquisition is a significant move for Novartis, as it gives it full exposure to IFM Tre's portfolio of NLRP3 inhibitors.
The NLRP3, the nucleotide-binding domain containing three pathway, is crucial to the body’s immune system and works as a warning sensor for pathogens signaling tissue damage and metabolic disorders.
The acquisition is significant as it means gaining control over IFM Tre's molecules that can selectively suppress inflammation caused by the NLRP3 inflammasome, while allowing the rest of the immune system to remain unaffected.
Momentum Indicator for NVS turns negative, indicating new downward trend
NVS saw its Momentum Indicator move below the 0 level on July 15, 2025. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 82 similar instances where the indicator turned negative. In of the 82 cases, the stock moved further down in the following days. The odds of a decline are at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for NVS moved out of overbought territory on July 03, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 similar instances where the indicator moved out of overbought territory. In of the 30 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Moving Average Convergence Divergence Histogram (MACD) for NVS turned negative on July 11, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NVS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
NVS broke above its upper Bollinger Band on July 01, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NVS advanced for three days, in of 342 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 311 cases where NVS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 81, placing this stock better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. NVS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.200) is normal, around the industry mean (5.632). P/E Ratio (23.383) is within average values for comparable stocks, (48.974). Projected Growth (PEG Ratio) (5.223) is also within normal values, averaging (3.004). Dividend Yield (0.039) settles around the average of (0.161) among similar stocks. P/S Ratio (4.299) is also within normal values, averaging (3.643).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of health care and nutritional products
Industry PharmaceuticalsMajor
Advertisement